ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1569

Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter

Janet Flores1, Diego Baenas2, Maria Jezabel Haye Salinas3, Soledad Retamozo4, Juan Pablo Pirola5, Nadia Benzaquén3, Nadia Riscanevo6, María Flavia Ceballos7, Ana C. Alvarez3, Verónica Saurit8, Alejandro Alvarellos9, Priscila Serravalle10, Alberto Ortiz11, Sergio Paira11 and Francisco Caeiro5, 1Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, 2Reumatologia, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 3Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 4Sociedad Argentina de Reumatologia, Córdoba, Argentina, 5Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 6Rheumatology, Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, 7Rheumatology, Rheumatology Unit, Hospital privado Universitario de Córdoba., Cordoba, Argentina, 8Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 9Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 10Hospital Cullen, Santa Fe, Argentina, 11Reumatologia, Hospital J M Cullen, Santa Fe, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biopsies and laboratory tests, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:Labial salivary gland biopsy (LSGB) is a safe and minimally invasive procedure used in the diagnostic evaluation of Sjogren’s Syndrome (SS). The objectives of this study are: to describe the demographic, clinical and histological characteristics of patients submitted for LSGB; to examine the usefulness of this procedure as a diagnostic tool for SS; to assess the association between histological findings and antibodies.

Methods: An observational, analytical, cross-sectional study was performed between June 1996 and July 2017. Patients with SS were classified according the AECG-2002 and ACR-2012 criteria. Grades III and IV biopsy of the Chisholm and Mason´s classification/focus score ≥1 were considered positive. Data was analyzed using the statistical package SPSS 21.

Results: 1101 patients were included, 91 % females. The mean age was 52 ± years(range18–86). SS was diagnosed in 413 (37.5%) patients. 34% of the biopsies were positive. Table 1 shows the clinical characteristics and complementary studies in patients with nonspecific dryness syndrome (No-SS) and SS. In bivariate analysis there was an association between antiRo, ANA and RF antibodies and LSGB. In multivariate analysis the significance for anti-Ro (OR: 6.33; 95% CI 3.22 to 12.15), ANA (OR: 3.26; 95% CI 2.15 to 4.94) and RF (OR: 3.05; 95% CI 2.04 to 4.56) was maintained.

Parameters

SS n (%)

No-SS n (%)

p

OR

Female

380/413 (92)

619/688 (90%)

0.284

1.284 (0.832-1.981)

Xerostomia

351/410 (85.6)

518/679 (76.3)

<0.001

1.85 (1.33-2.57)

Xerophthalmia

368/409 (90)

559/679 (82.3)

0.001

1.93 (1.32-2.81)

Parotidomegaly

90/404 (22.3)

58/673 (8.6)

<0.001

3.04 (2.13-4.34)

Abnormal ophtalmic test

260/277 (93.9)

237/355 (66.9)

<0.001

7.62 (4.45-13.04)

Abnormal salivary test

66/76 (86.8)

84/115 (73)

0.03

2.44 (1.11-5.33)

antiRo/SS-A

antiLa/SS-B

ANA

RF

120/366 (32.8)

49/366 (13.4)

194/387 (50.1)

176/394 (44.7)

18/558 (3.2)

3/557 (0.5)

82/606 (13.5)

115/618 (18.6)

<0.001

<0.001

<0.001

<0.001

14.63 (8.72-24.56)

28.55 (8.83-92.33)

6.42 (4.73-8.73)

3.53 (2.66-4.69)

LSGB G III

143/413 (34.6)

0/687 (0)

<0.001

3.54 (3.2-3.9)

LSGB G IV

227/413 (55)

0/687 (0)

<0.001

4.69 (4.13-5.33)

Parameters

Sensitivity

Specificity

PPV

NPV

LR

Ro/SS-A*

32.8

96.8

86.9

68.7

8

La/SS-B*

13.4

99.5

94.2

63.6

13

ANA*

50.1

86.5

70.2

73.1

3.57

RF*

44.7

81.4

60.4

69.7

2.3

Conclusion: LSGB is a simple, safe, and useful tool for the diagnosis of Sjögren’s syndrome. It exhibits an adequate balance between sensitivity, specificity, positive and negative predictive value. Antibodies showed a significant association with a positive LSGB with low sensitivity for SS screening but high specificity. LSGB has a great value in “seronegatives patients”.


Disclosure: J. Flores, None; D. Baenas, None; M. J. Haye Salinas, None; S. Retamozo, None; J. P. Pirola, None; N. Benzaquén, None; N. Riscanevo, None; M. F. Ceballos, None; A. C. Alvarez, None; V. Saurit, None; A. Alvarellos, None; P. Serravalle, None; A. Ortiz, None; S. Paira, None; F. Caeiro, None.

To cite this abstract in AMA style:

Flores J, Baenas D, Haye Salinas MJ, Retamozo S, Pirola JP, Benzaquén N, Riscanevo N, Ceballos MF, Alvarez AC, Saurit V, Alvarellos A, Serravalle P, Ortiz A, Paira S, Caeiro F. Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/diagnostic-performance-of-labial-salivary-gland-biosy-serological-and-clinical-data-in-sjogrens-syndrome-in-argentinian-multicenter/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-performance-of-labial-salivary-gland-biosy-serological-and-clinical-data-in-sjogrens-syndrome-in-argentinian-multicenter/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology